Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Busulfan and Fludarabine Conditioning for HSCT in Genetic Rare Disease
NCT02034630Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- Jul 2014
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan, sponsored by Seoul National University Hospital. Primary endpoint: Engraftment rate at 1 year. Status: unknown.
02
Drugs
busulfan
Beyond the preview
Go deeper on NCT02034630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034630.